Table 4.
Expression profiles of Dsg2 in normal skin and SCC
| Pathology (subtype) | Histology (differentiation state) | |||||||
| NHS | SCC | SCC | Recurring | Metastatic | Poor | Moderate | Well | |
| Dsg2 | (n=9) | (n=44) | (n=30) | (n=8) | (n=6) | (n=4) | (n=7) | (n=20) |
| 0 | 6 | 10 | 7 | 0 | 3 | 0 | 1 | 5 |
| +1 | 1 | 8 | 6 | 1 | 1 | 0 | 2 | 6 |
| +2 | 2 | 6 | 5 | 1 | 0 | 0 | 1 | 3 |
| +3 | 0 | 7 | 5 | 1 | 1 | 0 | 1 | 4 |
| +4 | 0 | 13 | 7 | 5 | 1 | 4 | 2 | 2 |
| Positive | 3/9* | 34/44** | 23/30 | 8/8 | 3/6 | 4/4 | 6/7 | 15/20 |
| staining | (33%) | (77%) | (77%) | (100%) | (50%) | (100%) | (86%) | (75%) |
Semi-quantitative assessment, 0, +1, +2, +3, +4. *Staining restricted to the basal cell layer in the interfollicular epidermis. **Staining extensive throughout tumor mass. NHS, normal human skin; SCC, squamous cell carcinoma.